LON:AZN AstraZeneca (AZN) Share Price, News & Analysis £106.62 +50.00 (+0.47%) As of 12:37 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityBuy This Stock About AstraZeneca Stock (LON:AZN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AstraZeneca alerts:Sign Up Key Stats Today's Range£104.84▼£107.6250-Day Range£100.22▼£109.8252-Week Range 9,573.51▼£133.88Volume1.20 million shsAverage Volume12.02 million shsMarket Capitalization£205.14 billionP/E Ratio29.22Dividend Yield2.19%Price TargetGBX 8,380Consensus RatingModerate Buy Company Overview AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca. Read More AstraZeneca Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreAZN MarketRank™: AstraZeneca scored higher than 37% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingModerate Buy Consensus RatingAstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAstraZeneca has only been the subject of 3 research reports in the past 90 days.Read more about AstraZeneca's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of AstraZeneca is 29.22, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.26.Price to Earnings Ratio vs. SectorThe P/E ratio of AstraZeneca is 29.22, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.58.Price to Earnings Growth RatioAstraZeneca has a PEG Ratio of 0.86. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAstraZeneca has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AZN. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldAstraZeneca pays a meaningful dividend of 1.23%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAstraZeneca does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of AstraZeneca is 64.14%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about AstraZeneca's dividend. Sustainability and ESG4.0 / 5Environmental Score-2.35 Short InterestThere is no current short interest data available for AZN. News and Social Media2.9 / 5News Sentiment0.24 News SentimentAstraZeneca has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for AstraZeneca this week, compared to 4 articles on an average week.Search Interest29 people have searched for AZN on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.MarketBeat Follows2 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AstraZeneca insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.04% of the stock of AstraZeneca is held by insiders.Percentage Held by Institutions51.03% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AstraZeneca's insider trading history. Receive AZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter. Email Address AZN Stock News HeadlinesAstraZeneca (LSE:AZN) Unveils Promising Phase III Results For Baxdrostat In Hypertension TrialJuly 14 at 3:15 PM | finance.yahoo.comAstraZeneca slips Friday, underperforms marketJuly 11 at 6:42 PM | marketwatch.comA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.July 14 at 2:00 AM | American Alternative (Ad)AstraZeneca (AZN) Receives a Buy from Berenberg BankJuly 10, 2025 | theglobeandmail.comAstraZeneca (AZN) Receives a Hold from Deutsche BankJuly 10, 2025 | theglobeandmail.comAstraZeneca climbs Tuesday, outperforms marketJuly 8, 2025 | marketwatch.comTop Analyst Reports for T-Mobile, AstraZeneca & ComcastJuly 8, 2025 | msn.comAstraZeneca: Just What The Doctor OrderedJuly 8, 2025 | seekingalpha.comSee More Headlines AZN Stock Analysis - Frequently Asked Questions How have AZN shares performed this year? AstraZeneca's stock was trading at £104.68 at the start of the year. Since then, AZN shares have increased by 1.9% and is now trading at £106.62. How do I buy shares of AstraZeneca? Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of AstraZeneca own? Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Intel (INTC), Advanced Micro Devices (AMD) and Johnson & Johnson (JNJ). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - General Sub-IndustryPharmaceutical Products Current SymbolLON:AZN CIKN/A Webwww.astrazeneca.com Phone+44-20-73045000FaxN/AEmployees83,500Year FoundedN/APrice Target and Rating Average Price Target for AstraZenecaGBX 8,380 High Price Target£140 Low Price TargetGBX 140 Potential Upside/Downside-21.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)GBX 364.83 Trailing P/E Ratio29.22 Forward P/E Ratio14.61 P/E Growth0.86Net Income£8.71 billion Net Margins13.01% Pretax MarginN/A Return on Equity17.76% Return on Assets7.68% Debt Debt-to-Equity Ratio73.83 Current Ratio0.93 Quick Ratio0.59 Sales & Book Value Annual Sales£66.95 billion Price / Sales3.06 Cash FlowGBX 274.15 per share Price / Cash Flow38.89 Book ValueGBX 2,630 per share Price / Book4.05Miscellaneous Outstanding Shares1,924,030,520Free FloatN/AMarket Cap£205.14 billion OptionableNot Optionable Beta0.17 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (LON:AZN) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.